| dc.contributor.advisor | Mugabo, Pirrie | |
| dc.contributor.author | Taha, Esraa | |
| dc.date.accessioned | 2022-11-09T11:48:08Z | |
| dc.date.available | 2022-11-09T11:48:08Z | |
| dc.date.issued | 2009 | |
| dc.identifier.uri | http://hdl.handle.net/11394/9435 | |
| dc.description | Magister Pharmaceuticae - MPharm | en_US |
| dc.description.abstract | Many studies have investigated the pharmacokinetics of anti-tuberculosis drugs in
patients infected with tuberculosis. However, little is known about the pharmacokinetics
of the drugs that are used in the treatment of multi-drug resistant tuberculosis (MDR-
TB). Therefore, the objective of the present study was to investigate the steady state
concentrations and the pharmacokinetics of ofloxacin, one of the drugs used in the
treatment of MDR-TB in patients infected with MDR-TB and patients with MDR-TB
co-infected with HIV
Plasma samples were drawn at different times over 24 hours after ofloxacin oral
administration. For the determination of ofloxacin plasma concentrations, the liquid
chromatography coupled with mass spectrometry analysis method was used. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | University of the Western Cape | en_US |
| dc.subject | Hiv | en_US |
| dc.subject | Mass spectrometry | en_US |
| dc.subject | Ofloxacin | en_US |
| dc.subject | Pharmacokinetics | en_US |
| dc.subject | Plasma levels | en_US |
| dc.title | Determination of plasma concentrations using Lc/ms and pharmacokinetics of ofloxacin in Patients with multi-drug resistant tuberculosis and In patients with multi-drug resistant tuberculosis co- Infected with hiv | en_US |
| dc.rights.holder | University of the Western Cape | en_US |
